Related Experiment Video

Updated: Mar 20, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

ERK1 as a Therapeutic Target for Dendritic Cell Vaccination against High-Grade Gliomas

Min-Chi Ku¹, Inan Edes², Ivo Bendix³

¹Berlin Ultrahigh Field Facility (B.U.F.F.), Max Delbrueck Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.

Molecular Cancer Therapeutics

|June 4, 2016

Abstract:

Glioma regression requires the recruitment of potent antitumor immune cells into the tumor microenvironment. Dendritic cells (DC) play a role in immune responses to these tumors. The fact that DC vaccines do not effectively combat high-grade gliomas, however, suggests that DCs need to be genetically modified specifically to promote their migration to tumor relevant sites. Previously, we identified extracellular signal-regulated kinase (ERK1) as a regulator of DC immunogenicity and brain autoimmunity. In the current study, we made use of modern magnetic resonance methods to study the role of ERK1 in regulating DC migration and tumor progression in a model of high-grade glioma. We found that ERK1-deficient mice are more resistant to the development of gliomas, and tumor growth in these mice is accompanied by a higher infiltration of leukocytes. ERK1-deficient DCs exhibit an increase in migration that is associated with sustained Cdc42 activation and increased expression of actin-associated cytoskeleton-organizing proteins. We also demonstrated that ERK1 deletion potentiates DC vaccination and provides a survival advantage in high-grade gliomas. Considering the therapeutic significance of these results, we propose ERK1-deleted DC vaccines as an additional means of eradicating resilient tumor cells and preventing tumor recurrence. Mol Cancer Ther; 15(8); 1975-87. ©2016 AACR.

Insights

Deleting extracellular signal-regulated kinase 1 (ERK1) enhances dendritic cell (DC) migration and boosts anti-glioma immunity. ERK1-deficient DC vaccines show promise for treating high-grade gliomas and preventing recurrence.

Area of Science:

Immunology
Neuro-oncology
Cellular Biology

Background:

Effective glioma regression necessitates robust antitumor immune cell infiltration into the tumor microenvironment.
Dendritic cells (DCs) are crucial for initiating anti-tumor immune responses, but current DC vaccines show limited efficacy against high-grade gliomas.
Genetic modification of DCs is needed to enhance their migration to tumor sites for improved therapeutic outcomes.

Purpose of the Study:

To investigate the role of extracellular signal-regulated kinase 1 (ERK1) in regulating DC migration and glioma progression using advanced magnetic resonance imaging.
To determine if ERK1 deficiency impacts glioma development and immune cell infiltration.
To evaluate the therapeutic potential of ERK1-deficient DCs in glioma treatment.

Main Methods:

Utilized a mouse model of high-grade glioma.
Employed modern magnetic resonance methods to study DC migration and tumor progression.
Analyzed leukocyte infiltration, DC migration, Cdc42 activation, and actin-associated cytoskeleton-organizing proteins in ERK1-deficient mice and DCs.

Main Results:

Mice lacking ERK1 exhibited increased resistance to glioma development and enhanced leukocyte infiltration.
ERK1-deficient DCs demonstrated improved migration capabilities, linked to sustained Cdc42 activation and altered cytoskeleton dynamics.
ERK1 deletion potentiated DC vaccination efficacy and conferred a survival advantage in high-grade glioma models.

Conclusions:

ERK1 plays a significant role in regulating DC migration and glioma progression.
Targeting ERK1 in DCs enhances their anti-tumor immune function and therapeutic potential.
ERK1-deleted DC vaccines represent a promising strategy for eradicating gliomas and preventing tumor recurrence.

Read full analysis

More Related Videos

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Articles linked to this work by shared authors, journal, and citation graph.

Cell-specific ERK2 signaling in vascular smooth muscle cells drives vascular dysfunction and systolic heart failure.

Journal of molecular and cellular cardiology·2026

MRI-scale histology validates spatial sensitivity of in-vivo MRI-based axon radius estimation.

Imaging neuroscience (Cambridge, Mass.)·2026

Degradation of biodegradable orthopedic screws does (not) elevate tissue heating under Magnetic Resonance Imaging: Implications for next generation implants.

Bioactive materials·2026

STK17A (DRAK1) at the crossroads of apoptosis, immunity, and cancer: Emerging roles and therapeutic opportunities.

Theranostics·2026

Trem2 exacerbates ischemic brain injury through Gpnmb in a photothrombotic stroke model.

Proceedings of the National Academy of Sciences of the United States of America·2026

Reply to Roesler et al. Comment on "Karaulic et al. Exploring Novel Applications: Repositioning Clinically Approved Therapies for Medulloblastoma Treatment. Cancers 2025, 17, 3659".

Cancers·2026

See all related articles